EUVIMEDEUVIMED entdecken
Fallbericht

Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis

Marie-Therese Holzer, Jasper F Nies, Tim Oqueka, Tobias B Huber, Ina Kötter, Martin Krusche

CHEST · 2023

DOI: 10.1016/j.chest.2022.08.2209 ↗

Kurz gefasst

Fallbericht in der Zeitschrift CHEST, 2023. Verfasst von Marie-Therese Holzer und 5 weiteren Autor:innen. Beteiligte Einrichtung: III Department of Medicine for Nephrology, Rheumatology and Endocrinology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Dermatomyositis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis is a rare systemic autoimmune disease that is associated with life-threatening rapidly progressive interstitial lung disease. We report the case of a 19-year-old male patient with a life-threatening disease course caused by rapidly progressive interstitial lung disease that caused respiratory failure despite intensive immunosuppression with multiple agents (steroids, IV immunoglobulins, tofacitinib, cyclophosphamide, mycophenolate mofetil, ciclosporin and rituximab). Rescue therapy with daratumumab, an anti-CD38-antibody, was initiated. Significant pulmonary improvement was noticed after 4 weekly injections of 1,800 mg. After 6 months of follow up, stable disease remission with significant pulmonary improvement and persistent depletion of CD38+ plasma cells and MDA5-antibody titers were seen. This is the first report of the successful use of daratumumab in dermatomyositis. It highlights the potential of CD38 targeted therapies for severe antibody-mediated autoimmune diseases such as dermatomyositis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisLung Diseases, InterstitialHumansMaleYoung AdultAutoantibodiesCyclophosphamideInterferon-Induced Helicase, IFIH1Antibodies, Monoclonal

Stichwörter der Autor:innen

anti-CD38, daratumumab, dermatomyositis, interstitial lung disease, MDA5

Substanzen

AutoantibodiesCyclophosphamideInterferon-Induced Helicase, IFIH1daratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • III Department of Medicine for Nephrology, Rheumatology and Endocrinology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • II Department of Medicine for Oncology and Pulmonology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • III Department of Medicine for Nephrology, Rheumatology and Endocrinology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: m.krusche@uke.de.

Zitieren

APA

Holzer, M. T., Nies, J. F., Oqueka, T., Huber, T. B., Kötter, I., & Krusche, M. (2023). Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis. CHEST. https://doi.org/10.1016/j.chest.2022.08.2209

Vancouver

Holzer MT, Nies JF, Oqueka T, Huber TB, Kötter I, Krusche M. Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis. CHEST. 2023. doi:10.1016/j.chest.2022.08.2209

BibTeX
@article{Holzer2023,
  author = {Holzer, Marie-Therese and Nies, Jasper F and Oqueka, Tim and Huber, Tobias B and Kötter, Ina and Krusche, Martin},
  title = {Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis},
  journal = {CHEST},
  year = {2023},
  doi = {10.1016/j.chest.2022.08.2209}
}
Kostenlos starten →